# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
- SEC Filing
CytomX Therapeutics (NASDAQ:CTMX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $...
HC Wainwright & Co. analyst Mitchell Kapoor reiterates CytomX Therapeutics (NASDAQ:CTMX) with a Neutral.
Piper Sandler analyst Joseph Catanzaro upgrades CytomX Therapeutics (NASDAQ:CTMX) from Neutral to Overweight and raises the ...
Initial data from CytomX Therapeutics' CX-904 Phase 1a study shows safety and anti-cancer activity in heavily pretreated pa...